
Kristine Kleivi Sahlberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5880083/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	True and Missed Interval Cancer in Organized Mammographic Screening: A Retrospective Review Study of Diagnostic and Prior Screening Mammograms. Academic Radiology, 2022, 29, S180-S191.	1.3	19
2	Abstract OT2-19-01: Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study. Cancer Research, 2022, 82, OT2-19-01-OT2-19-01.	0.4	0
3	NRF2 drives an oxidative stress response predictive of breast cancer. Free Radical Biology and Medicine, 2022, 184, 170-184.	1.3	8
4	miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. Breast Cancer: Targets and Therapy, 2022, Volume 14, 25-39.	1.0	3
5	Radiological review of prior screening mammograms of screen-detected breast cancer. European Radiology, 2021, 31, 2568-2579.	2.3	18
6	miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer. PLoS Computational Biology, 2021, 17, e1008608.	1.5	1
7	MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro. Scientific Reports, 2021, 11, 10893.	1.6	18
8	Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway. Radiology, 2020, 294, 256-264.	3.6	55
9	Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. Oncolmmunology, 2020, 9, 1824644.	2.1	17
10	miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Molecular Oncology, 2019, 13, 2278-2296.	2.1	30
11	An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nature Communications, 2019, 10, 5499.	5.8	132
12	DNA methylation at enhancers identifies distinct breast cancer lineages. Nature Communications, 2017, 8, 1379.	5.8	103
13	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer: Targets and Therapy, 2017, Volume 9, 185-198.	1.0	23
14	A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. Thrombosis Research, 2017, 157, 111-116.	0.8	21
15	Determinants of acquired activated protein C resistance and D-dimer in breast cancer. Thrombosis Research, 2016, 145, 78-83.	0.8	8
16	Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. Breast Cancer Research, 2015, 17, 44.	2.2	24
17	A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. Clinical Cancer Research, 2015, 21, 1207-1214.	3.2	191
18	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Medicine, 2015, 7, 21.	3.6	34

#	Article	IF	CITATIONS
19	Highâ€ŧhroughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Molecular Oncology, 2014, 8, 93-104.	2.1	146
20	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells — A data description. Genomics Data, 2014, 2, 249-253.	1.3	15
21	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Molecular Oncology, 2013, 7, 392-401.	2.1	80